A Phase 1 interventional study of Ferric Maltol in Iron Deficiency, Anaemia in Children and Iron-Deficiency, sponsored by Shield Therapeutics. Completed at 7 sites in United Kingdom. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-10-06.
Sponsored by Shield Therapeutics · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Iron Deficiencies with a site in United Kingdom — 2 open to participants now, 2 under way, none of them phase 3. Iron Deficiencies · United Kingdom.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 1, and was the 17th registered.
386 studies on the registry are indexed under Iron Deficiencies; 80 are open to participants now.
Browse Iron Deficiencies studies →2 of the 22 studies in Iron Deficiencies with a site in United Kingdom are open now. Recruiting first, the newest first:
University Hospital Southampton NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Quadram Institute Bioscience · Sites in United Kingdom
Ages 18–60 · Women only · Healthy volunteers
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 55 Iron Deficiencies studies recruiting now, 23 (42%) set no upper age limit and 28 (51%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 10 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2004; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 99 across 301 interventional studies indexed under Iron Deficiencies.
Median enrollment 50 across the 19 interventional studies, 379 across the 3 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 22 have an industry lead sponsor. The 10 most frequent:
Shield Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.
Shield Therapeutics has 4 studies filed under Iron Deficiencies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Iron Deficiencies with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study has been designed to establish the pharmacokinetics (PK) and iron uptake of Ferric Maltol in children and adolescents aged 10-17 years using two (2) lower dose strengths in comparison to the EU-approved 30mg BID dose in adults with IDA in IBD.
Phase I, open label, randomized, repeat dose, multicentre, pharmacokinetic study to assess the Safety and Tolerability of Ferric Maltol in 3 different dosages.
36 eligible patients will be randomized in a 1:1:1 ratio to one of the following 3 dosages for 9 days BID and a single dose on Day 10:
Subject participation in the study will consist of 3 stages:
Screening: up to 14 days Treatment period: 10 days treatment period with 2 visits on Day 1 and Day 10 for PK blood sampling. Patients will be randomly allocated to one of the three Ferric Maltol dose groups according to centralized treatment allocation scheme.
Post-treatment Safety Follow-up:3-10 days following completion of the treatment period or premature discontinuation of study medication
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
12 subjects will receive 30 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 30mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
Drug: Ferric Maltol
12 subjects will receive 16.6 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 16.6mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
Drug: Ferric Maltol
12 subjects will receive 7.8 mg Ferric Maltol twice daily for 9 days (Days 1-9) plus a final 7.8mg dose on the morning of Day 10. PK study Day 1 \& Day 10.
Drug: Ferric Maltol
To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
Also known as: ST10, Feraccru
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1
Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10
Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Area Under The Curve [AUC] of Maltol Glucuronide on Day 1
Descriptive statistics and population PK analysis of maltol glucuronide AUC from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Area Under The Curve [AUC] of Maltol Glucuronide on Day 10
Descriptive statistics and population PK analysis of maltol AUC from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Average Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 10
Descriptive statistics and population PK analysis of maltol glucuronide Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 1
Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 10
Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Half Life [t1/2] of Maltol Glucuronide on Day 1
Descriptive statistics and population PK analysis of maltol glucuronide t1/2 from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Ratio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 1
Descriptive statistics of ratio maltol glucuronide Cmax Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Ratio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 1
Descriptive statistics of ratio maltol glucuronide AUC Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 and Day 10, pre-dose and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Average Serum Concentration [Cave(0-6h)] of Iron on Day 10
Descriptive statistics and population PK analysis of iron Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 1
Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10
Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 1
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 10
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Systemic Clearance (CL/F) of Iron on Day 1
Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 1
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Systemic Clearance (CL/F) of Iron on Day 10
Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 10
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Volume of Distribution (V/F) of Iron on Day 1
Descriptive statistics and population PK analysis of iron V/F from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 1
Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 1
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Volume of Distribution (V/F) of Transferrin Saturation (TSAT) on Day 10
Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 10
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Ratio Auc(0-6) Maltol Glucuronide Day 10/Day 1
Ratio AUC0-6h measured after last dose of Ferric Maltol on Day 10 vs first dose Day 1.
Time frame: Day 1 to Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Serum Iron - RAUC(0-6h) D10/D1
Serum Iron - RAUC(0-6h) Day 10/Day 1
Time frame: Measured after first and last dose of Ferric Maltol on Day 1 & Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Transferrin Saturation (%) Day 1, Baseline
Transferrin Saturation (TSAT%) Day 1, baseline
Time frame: Measured after first dose of Ferric Maltol on Day 1 (0h)
Transferrin Saturation (%) Day 1, Maximum Response (%)
Transferrin Saturation (TSAT%) Day 1, maximum response (%)
Time frame: Measured after first dose of Ferric Maltol on Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Transferrin Saturation Day 1, Time to Maximum Response Tmax
Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Measured after first dose of Ferric Maltol on Day 1. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Transferrin Saturation (%) Day 10, Maximum Response (%)
Transferrin Saturation (TSAT%) Day 10, maximum response (%). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Transferrin Saturation Day 10, Time to Maximum Response Tmax
Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Measured after first dose of Ferric Maltol on Day 10. (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h).
AUC0-inf Day 1 for Maltol Glucuronide
AUC0-inf for Maltol Glucuronide from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Measured after first dose of Ferric Maltol on Day 1 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
AUC0-tau Day 10 for Maltol Glucuronide
AUC0-tau for Maltol Glucuronide from PK samples collected on Day 10. Area under the plasma concentration versus time curve from time 0 to tau.
Time frame: Measured after last dose of Ferric Maltol on Day 10. (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Cthrough for Maltol Glucuronide Day 10
Change from pre-dose to last PK samples collected on Day 10 for maltol glucuronide.Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 10 pre-dose to last (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Serum Iron Cmax Day 1
Maximum serum concentration of serum iron on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
Time frame: Day 1 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Serum Iron Cmax on Day 10
Maximum serum concentration of serum iron on Day 10.
Time frame: Day 10 (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Plasma Maltol Glucuronide Cthrough D10/Day1
Minimum concentration between dose time and dose time+TAU
Time frame: Day 10 (0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 1
Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 1
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h
Apparent Systemic Clearance (CL/F) of Transferrin Saturation (TSAT) on Day 10
Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 10
Time frame: Day 10 pre-final dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h)
Apparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 1
Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 1.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h
Apparent Systemic Clearance (CL/F) of Maltol Glucuronide on Day 10
Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 10.
Time frame: Day 1 pre-first dose of Ferric Maltol and up to 6 hours post-dose (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h
Transferrin - Change From Baseline to Day 10, Predose
Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose
Time frame: Day 1 pre-dose to Day 10 pre-dose (0h on each day)
Ferritin - Change From Baseline to Day 10, Predose
Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose.
Time frame: Pre-dose on Day 1 to Day 10 (0h)
Total Iron Binding Capacity - Change From Day 1 to Day 10, Predose
Change calculated as difference in values measured at Day 1, predose and on Day 10, predose
Time frame: Predose from Day 1 to Day 10 (0h on each day)
UIBC - Change From Day 1 to Day 10, Predose
Change calculated as difference in values measured at Day 1, predose and on Day 10, predose
Time frame: Pre-dose on Day 1 to Day 10 (0h each day)
Negative and Positive NTBI Tests on Day 1
Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 1, predose
Time frame: Day 1 (0h)
Change From Baseline to Day 10 in Haemoglobin Concentration
Change calculated as difference in values measured at Screening (Baseline) and on Day 10
Time frame: Screening and Day 10 (1-4 hours post-dose)
Change From Baseline to Day 10 in Absolute Reticulocyte Count
Change from Baseline to Day 10 in Absolute Reticulocyte Count collected from PK samples
Time frame: Change calculated as difference in values measured at Screening (Baseline) and on Day 10.
Treatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments
Descriptive summary of incidence and causal relationship of treatment-emergent adverse events leading to discontinuation of study drug/PK assessments according to MedDRA preferred term (PT) and system organ class (SOC)
Time frame: From first dose of Ferric Maltol on Day 1 through study completion, on average 4 weeks
Changes in 12-lead ECG Parameters From Screening to Day 10
Overall clinical interpretation of routine ECG parameters from Screening to Day 10
Time frame: Screening and Day 10 (1-4 hours post-dose)
Concomitant Medications
Number of subjects with concomitant medications Taken by \>5% of Subjects
Time frame: Screening, Day 1, Day 10 and Post-Study Follow-up visit, on average 4 weeks
Negative and Positive NTBI Tests on Day 10, Predose
Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 10, predose
Time frame: Day 10
Treatment-emergent Serious Adverse Event (TESAE)
Descriptive summary of TESAE according to MedDRA preferred Term
Time frame: From first dose of ferric maltol Day 1 through study completions, on average 4 weeks
| Milestone | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Started | 12 | 13 | 12 |
| Completed | 12 | 11 | 12 |
| Not completed | 0 | 2 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 |
Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 1 | 2.4518 ± 1.29590 | 1.1632 ± 0.18435 | 0.5299 ± 0.02245 |
Descriptive statistics and population PK analysis of maltol glucuronide Cmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10 | 4.2355 ± 0.78110 | 2.1028 ± 0.13342 | 0.9926 ± 0.02349 |
Descriptive statistics and population PK analysis of maltol glucuronide AUC from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Area Under The Curve [AUC] of Maltol Glucuronide on Day 1 | 11.090 ± 3.9033 | 5.613 ± 0.7589 | 2.585 ± 0.0968 |
Descriptive statistics and population PK analysis of maltol AUC from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Area Under The Curve [AUC] of Maltol Glucuronide on Day 10 | 20.511 ± 1.7997 | 10.518 ± 0.5277 | 5.016 ± 0.1133 |
Descriptive statistics and population PK analysis of maltol glucuronide Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Average Plasma Concentration [Cave(0-6h)] of Maltol Glucuronide on Day 10 | 3.4186 ± 0.29995 | 1.7531 ± 0.08795 | 0.8360 ± 0.01889 |
Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 1 | 1.00 (0.75 to 1.00) | 1.00 (0.75 to 1.00) | 1.00 (1.00 to 1.00) |
Descriptive statistics and population PK analysis of maltol glucuronide Tmax from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Time of Maximum Plasma Concentration [Tmax] of Maltol Glucuronide on Day 10 | 0.75 (0.75 to 0.75) | 0.75 (0.75 to 0.75) | 0.75 (0.75 to 0.75) |
Descriptive statistics and population PK analysis of maltol glucuronide t1/2 from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Half Life [t1/2] of Maltol Glucuronide on Day 1 | 11.384 ± 5.4738 | 10.447 ± 1.8503 | 10.806 ± 0.4707 |
Descriptive statistics of ratio maltol glucuronide Cmax Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| ratio | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Ratio of Maximum Plasma Concentration [Cmax] of Maltol Glucuronide on Day 10/Day 1 | 1.956 ± 0.6210 | 1.836 ± 0.2109 | 1.875 ± 0.0537 |
Descriptive statistics of ratio maltol glucuronide AUC Day 10/Day 10 from PK samples collected on Day 1 and Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| ratio | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Ratio of Area Under The Curve [AUC] of Maltol Glucuronide on Day 10/Day 1 | 2.030 ± 0.6695 | 1.899 ± 0.2286 | 1.942 ± 0.0582 |
Descriptive statistics and population PK analysis of iron Cave(0-6h) from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Average Serum Concentration [Cave(0-6h)] of Iron on Day 10 | 1.1667 ± 0.61420 | 0.9557 ± 0.29645 | 0.9748 ± 0.39783 |
Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 1 | 0.6159 ± 0.32320 | 0.4102 ± 0.22144 | 0.21715 ± 0.11873 |
Descriptive statistics and population PK analysis of change in serum iron \[Ctrough to Cmax\] from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Change From Pre-Dose (Ctrough) to Maximum Post-Dose (Cmax) in Serum Iron on Day 10 | 0.5486 ± 0.32367 | 0.3625 ± 0.15333 | 0.2251 ± 0.08362 |
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 1 | 6.711 ± 2.5721 | 5.963 ± 1.7793 | 3.928 ± 1.1318 |
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of serum iron from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*mg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Serum Iron on Day 10 | 7.000 ± 3.6852 | 5.734 ± 1.7787 | 5.849 ± 2.3870 |
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*% | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 1 | 179.47 ± 60.259 | 159.21 ± 50.723 | 104.50 ± 41.009 |
Descriptive statistics and population PK analysis of pre-dose adjusted incremental AUC(0-6h) of TSAT from PK samples collected on Day 10. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h*% | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Pre-dose Adjusted Incremental Area Under the Curve [AUC(0-6h)] of Transferrin Saturation (TSAT) on Day 10 | 180.14 ± 76.193 | 149.40 ± 37.799 | 157.43 ± 81.693 |
Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 1
| L/h | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Apparent Systemic Clearance (CL/F) of Iron on Day 1 | 1.321 ± 0.6945 | 0.654 ± 0.2441 | 0.324 ± 0.1517 |
Descriptive statistics and population PK analysis of serum iron CL/F from PK samples collected on Day 10
| L/h | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Apparent Systemic Clearance (CL/F) of Iron on Day 10 | 3.264 ± 2.2297 | 1.757 ± 0.6673 | 0.808 ± 0.3089 |
Descriptive statistics and population PK analysis of iron V/F from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Apparent Volume of Distribution (V/F) of Iron on Day 1 | 22.114 ± 7.2315 | 14.244 ± 4.8083 | 10.462 ± 3.1033 |
Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 1
No measurements were reported for this outcome.
Descriptive statistics and population PK analysis of TSAT V/F from PK samples collected on Day 10
No measurements were reported for this outcome.
Ratio AUC0-6h measured after last dose of Ferric Maltol on Day 10 vs first dose Day 1.
| Ratio | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Ratio Auc(0-6) Maltol Glucuronide Day 10/Day 1 | 1.942 ± 0.0582 | 1.899 ± 0.2286 | 2.030 ± 0.6695 |
Serum Iron - RAUC(0-6h) Day 10/Day 1
| Ratio | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Serum Iron - RAUC(0-6h) D10/D1 | 1.529 ± 1.4673 | 1.020 ± 0.3170 | 1.038 ± 0.3973 |
Transferrin Saturation (TSAT%) Day 1, baseline
| percentage saturation | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Transferrin Saturation (%) Day 1, Baseline | 11.5 ± 5.66 | 16.8 ± 9.25 | 15.8 ± 9.31 |
Transferrin Saturation (TSAT%) Day 1, maximum response (%)
| percentage saturation | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Transferrin Saturation (%) Day 1, Maximum Response (%) | 18.68 ± 7.13 | 28.261 ± 8.4784 | 32.845 ± 10.5913 |
Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| hour | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Transferrin Saturation Day 1, Time to Maximum Response Tmax | 4.00 (2.00 to 4.00) | 3.00 (2.00 to 4.00) | 3.00 (3.00 to 5.00) |
Transferrin Saturation (TSAT%) Day 10, maximum response (%). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| percentage saturation | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Transferrin Saturation (%) Day 10, Maximum Response (%) | 27.779 ± 13.863 | 27.214 ± 6.699 | 33.524 ± 13.633 |
Transferrin Saturation (TSAT%) Day 1, time to maximum response Tmax (h). Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| hour | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Transferrin Saturation Day 10, Time to Maximum Response Tmax | 3.00 (0.00 to 4.00) | 3.00 (0.00 to 4.00) | 3.00 (0.00 to 4.00) |
AUC0-inf for Maltol Glucuronide from PK samples collected on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| h.mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| AUC0-inf Day 1 for Maltol Glucuronide | 8.590 ± 0.2025 | 17.862 ± 0.9328 | 34.372 ± 4.5052 |
AUC0-tau for Maltol Glucuronide from PK samples collected on Day 10. Area under the plasma concentration versus time curve from time 0 to tau.
| h mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| AUC0-tau Day 10 for Maltol Glucuronide | 8.59 ± 0.2024 | 17.862 ± 0.9327 | 34.368 ± 4.4981 |
Change from pre-dose to last PK samples collected on Day 10 for maltol glucuronide.Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Cthrough for Maltol Glucuronide Day 10 | 0.4804 ± 0.01639 | 0.9762 ± 0.10586 | 1.8496 ± 0.67761 |
Maximum serum concentration of serum iron on Day 1. Each subject had 1 pre-dose (0h) and 2 post dose PK blood sampling between (0h, 0.5-1h, 1-2h, 2-3h, 3-4h, 4-6h). Subjects were assigned to PK blood sampling schedule. For each individual subject the PK blood sampling schedule was the same on Day 1 and Day 10.
| mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Serum Iron Cmax Day 1 | 0.7030 ± 0.19765 | 1.681 ± 0.30405 | 1.2328 ± 0.47471 |
Maximum serum concentration of serum iron on Day 10.
| mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Serum Iron Cmax on Day 10 | 1.0338 ± 0.4023 | 1.0462 ± 0.3221 | 1.3034 ± 0.6741 |
Minimum concentration between dose time and dose time+TAU
| mg/L | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Plasma Maltol Glucuronide Cthrough D10/Day1 | 0.4804 ± 0.0163 | 0.9762 ± 0.105 | 1.8496 ± 0.677 |
Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 1
No measurements were reported for this outcome.
Descriptive statistics and population PK analysis of serum TSAT CL/F from PK samples collected on Day 10
No measurements were reported for this outcome.
Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose
| g/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Transferrin - Change From Baseline to Day 10, Predose | -0.085 ± 0.1510 | -0.147 ± 0.1419 | 0.032 ± 0.2275 |
Change calculated as difference in values measured at Day 1, predose (Baseline) and on Day 10, predose.
| μg/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Ferritin - Change From Baseline to Day 10, Predose | 7.3 ± 8.22 | 4.1 ± 3.73 | 0.5 ± 4.95 |
Change calculated as difference in values measured at Day 1, predose and on Day 10, predose
| umol/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Total Iron Binding Capacity - Change From Day 1 to Day 10, Predose | -2.12 ± 3.406 | -3.11 ± 3.201 | 1.13 ± 4.452 |
Change calculated as difference in values measured at Day 1, predose and on Day 10, predose
| umol/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| UIBC - Change From Day 1 to Day 10, Predose | -2.10 ± 7.775 | -2.33 ± 5.525 | -4.49 ± 8.343 |
Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 1, predose
| Participants | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Positive | 0 | 0 | 0 |
| Negative | 12 | 13 | 12 |
Change calculated as difference in values measured at Screening (Baseline) and on Day 10
| g/dL | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Change From Baseline to Day 10 in Haemoglobin Concentration | -0.03 ± 0.789 | -0.33 ± 1.097 | -0.45 ± 0.301 |
Change from Baseline to Day 10 in Absolute Reticulocyte Count collected from PK samples
| cells*10^12/L | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Change From Baseline to Day 10 in Absolute Reticulocyte Count | 0.036 ± 0.0114 | -0.001 ± 0.0218 | 0.016 ± 0.0358 |
Descriptive summary of incidence and causal relationship of treatment-emergent adverse events leading to discontinuation of study drug/PK assessments according to MedDRA preferred term (PT) and system organ class (SOC)
| Participants | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Treatment-emergent Adverse Events (AEs) Leading to Premature Discontinuation of Study Drug/PK Assessments | 0 | 1 | 0 |
Overall clinical interpretation of routine ECG parameters from Screening to Day 10
| Participants | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Normal | 10 | 11 | 12 |
| Abnormal | 0 | 0 | 0 |
Number of subjects with concomitant medications Taken by \>5% of Subjects
| Participants | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Concomitant Medications | 8 | 13 | 10 |
Negative and Positive Non-Transferrin Bound Iron \[NTBI\] tests on Day 10, predose
| Participants | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| Positive | 1 | 0 | 0 |
| Negative | 11 | 11 | 10 |
Descriptive summary of TESAE according to MedDRA preferred Term
| Participants | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol |
|---|---|---|---|
| Treatment-emergent Serious Adverse Event (TESAE) | 0 | 0 | 0 |
Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 1.
No measurements were reported for this outcome.
Descriptive statistics and population PK analysis of plasma maltol glucuronide CL/F from PK samples collected on Day 10.
No measurements were reported for this outcome.
Collected over 10 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 30 mg Ferric Maltol | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| 16.6 mg Ferric Maltol | 0/13 (0%) | 0/13 (0%) | 7/13 (53.8%) |
| 7.8 mg Ferric Maltol | 0/12 (0%) | 0/12 (0%) | 7/12 (58.3%) |
| Event | 30 mg Ferric Maltol | 16.6 mg Ferric Maltol | 7.8 mg Ferric Maltol |
|---|---|---|---|
| HeadacheNervous system disorders | 4/12 | 2/13 | 1/12 |
| Faeces discolouredGastrointestinal disorders | 3/12 | 1/13 | 1/12 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 0/13 | 2/12 |
| FatigueGeneral disorders | 2/12 | 1/13 | 1/12 |
| DizzinessNervous system disorders | 2/12 | 1/13 | 0/12 |
| PalpitationsCardiac disorders | 0/12 | 0/13 | 1/12 |
| NauseaGastrointestinal disorders | 1/12 | 0/13 | 1/12 |
| VomitingGastrointestinal disorders | 0/12 | 1/13 | 1/12 |
| Abdominal distensionGastrointestinal disorders | 1/12 | 0/13 | 0/12 |
| Abdominal painGastrointestinal disorders | 1/12 | 0/13 | 0/12 |
| Age, Continuous(years) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Mean | 14.1 ± 1.56 | 13.7 ± 1.80 | 14.2 ± 2.12 | 14.0 ± 1.80 |
| Age, Customized(Participants) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| 10-14 | 8 | 7 | 8 | 23 |
| 15-17 | 4 | 6 | 4 | 14 |
| Sex: Female, Male(Participants) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Female | 8 | 8 | 8 | 24 |
| Male | 4 | 5 | 4 | 13 |
| Race/Ethnicity, Customized(Participants) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Ethnicity — Not Hispanic or Latino | 11 | 13 | 11 | 35 |
| Ethnicity — Unknown | 1 | 0 | 1 | 2 |
| Height(m) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Mean | 1.590 ± 0.0641 | 1.601 ± 0.855 | 1.618 ± 0.0914 | 1.603 ± 0.0799 |
| Weight(kg) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Mean | 57.83 ± 20.961 | 62.77 ± 23.330 | 52.07 ± 9.661 | 57.41 ± 18.758 |
| BMI(kg/m^2) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Mean | 22.695 ± 7.4067 | 24.265 ± 7.7647 | 19.760 ± 2.7049 | 22.182 ± 6.4355 |
| Haemoglobin(g/dL) | 7.8 mg Ferric Maltol | 16.6 mg Ferric Maltol | 30 mg Ferric Maltol | Total |
|---|---|---|---|---|
| Mean | 12.27 ± 0.856 | 12.75 ± 1.067 | 12.37 ± 1.418 | 12.47 ± 1.124 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Mar 2018, 12 months.
Results were first posted in Jun 2020, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric maltol
Shield Therapeutics